MS patients on B-cell depleting therapies are still protected against COVID-19 risk due to greater anti-viral T-cell activity ...

Sechs neue Arzneistoffe bereichern seit 2020 die Therapieoptionen bei Multipler Sklerose (MS). Auch sie greifen in das ...

Seven years ago, actress Selma Blair was diagnosed with multiple sclerosis, but it took a female doctor to make real headway in her healing process. Last year, Selma revealed she fell into a major ...

Ublituximab (Briumvi) and Rituximab (Rituxan, Ruxience, Truxima) are also anti-CD20 monoclonal antibodies used to treat MS. (Ublituximab is FDA-approved for MS, while rituximab is used off-label.) ...

Rituximab is the third type of B cell therapy used to treat MS. Unlike the other two, the FDA hasn’t approved it for MS. But some doctors may use it “off label” to treat MS. Rituximab is an ...

About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...

About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...

It was the late ’90s and UCSF Neurology Professor Stephen Hauser, M.D., and team had applied for federal funding for the first clinical trial of the new medicine, rituximab, as a potential MS ...

After Cherie Binns had breakthrough multiple sclerosis symptoms while being treated with an interferon drug, she weighed her options carefully. In the end, her neurologist prescribed rituximab.